Changhai Hostipal
Shanghai, Shanghai Municipality, China
NCT Number: NCT05940987
This study aims to explore whether regular telephone intervention in patients with chronic pancreatitis can improve their smoking cessation rate.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Shanghai, Shanghai Municipality, China
Chronic pancreatitis(CP) is a chronically progressive disease characterized by pancreatic fibrosis and inflammation, and its basic pathological features include chronic inflammatory damage to the pancreatic parenchyma, interstitial fibrosis, pancreatic parenchymal calcification, pancreatic duct dilation, and pancreatic duct stones.
Environmental factors such as alcoholism,smoking and genetic factors are the main causative factors of CP. Clinical studies have found that smoking can not only accelerate the course of CP, but also increase the risk of CP-related complications. Some scholars believe that smoking cessation may be a potential way to prevent the progression of CP and improve the prognosis of CP. Although there is no evidence to verify whether smoking cessation will improve the clinical course of CP, the latest ACG Clinical Guideline strongly recommends CP patients quit smoking.
In 2016,a prospective study of smoking cessation interventions in CP patients showed that 27 enrolled patients had a smoking cessation rate of 0% after 6 months of smoking cessation intervention, indicating that smoking cessation is a huge challenge for CP patients.
The investigators propose to conduct a randomized controlled trial to investigate the effects of telephone intervention on smoking cessation in patients with CP and explore the impact of smoking cessation on their clinical course and prognosis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
1.18 years of age and older living; 2.Patients diagnosed as chronic pancreatitis; 3.Self-reported smoking ≥ 5 cigarettes; 4.Urine cotinine levels ≥ 200 ng/mL; 5.Owning a phone; 6.Willing to provide informed consent to participate in the study.
Exclusion criteria
Participants who allocate to the intervention group will receive regular phone-based smoking cessation intervention by professional team.
Time frame: 12 months
The primary outcome will be biochemical validation of Self-reported 7-day point-prevalence abstinence at month 2, 6, 12 after quit date.
Time frame: 12 months
Self-reported 7-day point-prevalence abstinence at month 2, 6, 12 after quit date.
Time frame: 12 months
Mean number of cigarettes smoked per day among participants still smoking at 12 months.
Time frame: 12 months
The FTND is a validated, 6-item self-report instrument that evaluates the intensity of physical addiction to nicotine. The scores will be assessed at month 2, 6, 12 after quit date.Three items are rated yes/no (0/1), and the other three items are rated on a scale from 0-3. Items are summed to yield a total score of 0-10, with higher scores reflecting greater nicotine dependence. This outcome variable will be reported as the difference in FTND total score between the intervention condition and the control condition.
Time frame: 12 months
The number of CP patients who self-reported a 50% reduction in tobacco consumption at 2, 6 and 12 months after quit date.
Time frame: 12 months
The times of hospitalizations for episodes of chronic pancreatitis at 12 months after quit date.
Changhai Hospital
Other
Phone-based Smoking Cessation Intervention for Patients With Chronic Pancreatitis :a Prospective Multicenter Randomized Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05289362
Chronic Disease, Digestive System Diseases
Shanghai, China
View Trial DetailsNCT05270434
Chronic Disease, Digestive System Diseases
Shanghai, China
View Trial DetailsNCT06907953
COVID-19, Chronic Disease
New York, United States
View Trial DetailsNCT05772234
Chronic Disease, Digestive System Diseases
Shanghai, Shanghai Municipality, China
View Trial Details